Therapy with thalidomide in refractory multiple myeloma patients - The revival of an old drug

A. Kneller; P. Raanani; I. Hardan; A. Avigdor; I. Levi; M. Berkowicz; I. Ben-Bassat

doi:10.1046/j.1365-2141.2000.01835.x

Therapy with thalidomide in refractory multiple myeloma patients - The revival of an old drug

A. Kneller, P. Raanani, I. Hardan, A. Avigdor, I. Levi, M. Berkowicz, I. Ben-Bassat^*

^*Corresponding author for this work

Clinical Departments

Research output: Contribution to journal › Article › peer-review

139 Scopus citations

Abstract

We have treated 17 refractory or relapsed multiple myeloma patients resistant to chemotherapy with thalidomide at a dose of 200-800 mg/day. Eleven patients responded, five of whom had a very good partial response (> 75% decline in M protein) and another five exhibited a partial response (> 50% decline in M protein). Except for one patient, treatment was well tolerated with only mild side-effects. Thalidomide should be included in the therapeutic options for refractory myeloma.

Original language	English
Pages (from-to)	391-393
Number of pages	3
Journal	British Journal of Haematology
Volume	108
Issue number	2
DOIs	https://doi.org/10.1046/j.1365-2141.2000.01835.x
State	Published - 2000

Keywords

Multiple myeloma
Thalidomide

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1046/j.1365-2141.2000.01835.x

Cite this

@article{442dabfd51764019bc4338546b2c8552,

title = "Therapy with thalidomide in refractory multiple myeloma patients - The revival of an old drug",

abstract = "We have treated 17 refractory or relapsed multiple myeloma patients resistant to chemotherapy with thalidomide at a dose of 200-800 mg/day. Eleven patients responded, five of whom had a very good partial response (> 75% decline in M protein) and another five exhibited a partial response (> 50% decline in M protein). Except for one patient, treatment was well tolerated with only mild side-effects. Thalidomide should be included in the therapeutic options for refractory myeloma.",

keywords = "Multiple myeloma, Thalidomide",

author = "A. Kneller and P. Raanani and I. Hardan and A. Avigdor and I. Levi and M. Berkowicz and I. Ben-Bassat",

year = "2000",

doi = "10.1046/j.1365-2141.2000.01835.x",

language = "אנגלית",

volume = "108",

pages = "391--393",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - Therapy with thalidomide in refractory multiple myeloma patients - The revival of an old drug

AU - Kneller, A.

AU - Raanani, P.

AU - Hardan, I.

AU - Avigdor, A.

AU - Levi, I.

AU - Berkowicz, M.

AU - Ben-Bassat, I.

PY - 2000

Y1 - 2000

N2 - We have treated 17 refractory or relapsed multiple myeloma patients resistant to chemotherapy with thalidomide at a dose of 200-800 mg/day. Eleven patients responded, five of whom had a very good partial response (> 75% decline in M protein) and another five exhibited a partial response (> 50% decline in M protein). Except for one patient, treatment was well tolerated with only mild side-effects. Thalidomide should be included in the therapeutic options for refractory myeloma.

AB - We have treated 17 refractory or relapsed multiple myeloma patients resistant to chemotherapy with thalidomide at a dose of 200-800 mg/day. Eleven patients responded, five of whom had a very good partial response (> 75% decline in M protein) and another five exhibited a partial response (> 50% decline in M protein). Except for one patient, treatment was well tolerated with only mild side-effects. Thalidomide should be included in the therapeutic options for refractory myeloma.

KW - Multiple myeloma

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=0034014693&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2000.01835.x

DO - 10.1046/j.1365-2141.2000.01835.x

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:0034014693

SN - 0007-1048

VL - 108

SP - 391

EP - 393

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 2

ER -

Therapy with thalidomide in refractory multiple myeloma patients - The revival of an old drug

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this